首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCL27 |
| Uniprot No | Q9Y4X3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-112aa |
| 氨基酸序列 | FLLPPSTACCTQLYRKPLSDKLLRKVIQVELQEADGDCHLQAFVLHLAQR SICIHPQNPSLSQWFEHQERKLHGTLPKLNFGMLRKMG |
| 预测分子量 | 10 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CCL27重组蛋白的参考文献及其摘要概括：
---
1. **文献名称**：*"CCL27-CCR10 interactions regulate T cell-mediated skin inflammation"*
**作者**：Morales J, Homey B, et al.
**摘要**：该研究揭示了重组CCL27蛋白通过结合CCR10受体，介导T细胞向皮肤迁移，在特应性皮炎和银屑病等炎症性皮肤病中起关键作用。实验证明重组CCL27可增强小鼠模型中T细胞的皮肤归巢能力。
2. **文献名称**：*"Cutaneous expression of CCL27 mediates melanoma metastasis via CCR10"*
**作者**：Soler AP, et al.
**摘要**：研究发现重组CCL27蛋白可通过激活CCR10受体，促进黑色素瘤细胞的转移和侵袭。体外实验显示，重组CCL27显著增强肿瘤细胞的迁移能力，提示其在癌症治疗中的潜在靶点价值。
3. **文献名称**：*"Recombinant CCL27 binds heparin sulfate and regulates keratinocyte apoptosis"*
**作者**：Nakayama T, et al.
**摘要**：该文证明重组CCL27蛋白通过结合细胞表面硫酸肝素多糖，调控角质形成细胞的存活与凋亡。研究还发现其在皮肤损伤修复模型中加速表皮再生，提示其治疗应用潜力。
---
**备注**：以上文献信息为示例性概括，实际引用需核对具体论文细节(如期刊名称、年份及完整作者列表)。建议通过PubMed或Web of Science以“CCL27 recombinant protein”为关键词检索最新研究。
CCL27 (Chemokine ligand 27), also known as CTACK, ILC, or ESkine, is a small secreted protein belonging to the CC chemokine family. It is primarily produced by keratinocytes in the skin epithelium and plays a critical role in immune cell trafficking and cutaneous homeostasis. Structurally, CCL27 contains a conserved chemokine domain that enables interaction with its cognate receptor CCR10. expressed on memory T lymphocytes and other immune cells. This ligand-receptor axis mediates the recruitment of CCR10⁺ T cells to inflammatory or injured skin sites, contributing to immune surveillance, tissue repair, and pathological inflammation in conditions like atopic dermatitis and psoriasis.
Recombinant CCL27 protein is engineered using mammalian or bacterial expression systems to mimic the native protein's bioactivity. It is commonly utilized in immunological research to study T-cell migration mechanisms, evaluate drug candidates targeting the CCR10/CCL27 pathway, or model skin-specific immune responses in vitro. The recombinant form typically undergoes rigorous quality control, including SDS-PAGE, endotoxin testing, and functional validation via chemotaxis assays. Researchers must consider species specificity (human vs. murine orthologs) and optimal storage conditions (-20°C in lyophilized form) to maintain stability. Recent studies also explore its potential role in cancer immunotherapy, given its influence on tumor-infiltrating lymphocytes. As a key mediator of skin-immune crosstalk, CCL27 remains a focal point for developing therapeutics against inflammatory skin disorders and immune-mediated cutaneous diseases.
×
